FDA briefing package supports PH-762 Phase 2b plan
Phio Pharmaceuticals filed an FDA meeting request with a briefing package to support PH-762’s next-stage clinical development in cutaneous squamous cell carcinoma.
Submission follows completion of a Phase 1b trial; Phio outlined a planned Phase 2b neoadjuvant study.
Clinical supply manufacturing is underway; availability targeted for Q1 2027.
PHIO•
